Dewandel, Isabelle
van Niekerk, Margaret
Ghimenton-Walters, Elisabetta
Palmer, Megan
Anthony, Michaile G.
McKenzie, Carla
Croucamp, Rolanda
Alter, Galit
Demers, Anne-Marie
van Zyl, Gert
Claassen, Mathilda
Goussard, Pierre
Swanepoel, Ruan
Hoddinott, Graeme
Bosch, Corne
Dunbar, Rory
Allwood, Brian
McCollum, Eric D.
Schaaf, H. Simon
Hesseling, Anneke C.
van der Zalm, Marieke M.
Funding for this research was provided by:
R01 grant (R01AI152158)
EDCTP2 (TMA2019SFP-2836 TB lung-FACT2)
Researcher-initiated grant SAMRC
Fogarty International Centre of the NIH (K43TW011028)
Article History
Received: 8 December 2022
Accepted: 17 January 2023
First Online: 22 March 2023
Declarations
:
: Study protocol, ICF and other relevant study documents have been approved by the relevant Ethics Committees. The study was approved by the local Health Research Ethics Committee of Stellenbosch University (N17/08/083). All investigations are performed in accordance with the South African and internationally accepted ethical standards and regulations, including the Declaration of Helsinki and the South African Good Clinical Practice guidelines. Informed consent is obtained from the parents/legal caregivers of all study participants.
: Not applicable.
: Galit Alter is an employee of Moderna Therapeutics and an equity holder in Leyden Labs and Seromyx Systems, only after study set-up and enrolment. All other authors declare that they have no competing interests. This study has received multiple awards which are reported under the funding section.